Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

Conditions studied

Asthma in Children, Asthma Attack

About this study

This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.

Interventions

• Drug: Magnesium Sulfate within the first hour — The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg
• Other: No Magnesium sulfate within the first hour — The control group will not receive IV magnesium sulfate within the first hour of treatment.

Primary outcomes

• Change in Length of Stay in Patients who receive IV Magnesium within the first hour (experimental group) vs control group (From initiation of therapy to discharge from the emergency department or admitting unit, up to 1 week)

Eligibility information

Study locations

• Oklahoma Children's Hospital, Oklahoma City, Oklahoma 73104 United States